Royalty Pharma
RPRX
279 hedge funds and large institutions have $10.5B invested in Royalty Pharma in 2022 Q1 according to their latest regulatory filings, with 52 funds opening new positions, 130 increasing their positions, 59 reducing their positions, and 36 closing their positions.
902% more call options, than puts
Call options by funds: $39.2M | Put options by funds: $3.92M
120% more repeat investments, than reductions
Existing positions increased: 130 | Existing positions reduced: 59
44% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 36
5% more funds holding
Funds holding: 266 → 279 (+13)
0.01% less ownership
Funds ownership: 62.46% → 62.46% (-0.01%)
1% less capital invested
Capital invested by funds: $10.7B → $10.5B (-$155M)
18% less funds holding in top 10
Funds holding in top 10: 11 → 9 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$241M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$87.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$61.1M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$53.8M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$44.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Berkshire Hathaway
Omaha,
Nebraska
|
-$281M |
| 2 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$138M |
| 3 |
Morgan Stanley
New York
|
-$106M |
| 4 |
VCG
Vantage Consulting Group
Virginia Beach,
Virginia
|
-$73.6M |
| 5 |
MSKCC
Memorial Sloan Kettering Cancer Center
New York
|
-$61M |
RPRX Hedge Fund Activity: Q1 2022 in Review
279 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q1 2022, worth a combined $10.5B — down 1.4% from $10.7B a quarter earlier.
Buyers outnumbered sellers: 52 funds opened new RPRX positions and 36 closed out — a net gain of 16 holders — while 130 added to existing stakes and 59 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $241M. The largest seller was Berkshire Hathaway, cutting an estimated $281M.
- 279 institutional investors held Royalty Pharma (RPRX) as of Q1 2022, up from 266 in Q4 2021.
- Funds reported $10.5B of Royalty Pharma stock for Q1 2022, down 1.4% quarter-over-quarter.
- 52 funds opened new Royalty Pharma positions in Q1 2022 and 36 closed out, a net change of +16 holders.
- The largest Royalty Pharma buyer in Q1 2022 was Fidelity Investments, an estimated $241M added.
- The largest Royalty Pharma seller in Q1 2022 was Berkshire Hathaway, an estimated $281M sold.
Based on aggregated 13F filings for Q1 2022.